Nov 04, 2024 8:00am EST bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
Oct 21, 2024 10:45am EDT bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
Oct 18, 2024 12:45pm EDT bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
Oct 16, 2024 8:00am EDT bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
Oct 09, 2024 8:00am EDT bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
Sep 18, 2024 8:00am EDT Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
Aug 23, 2024 5:15pm EDT bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
Aug 14, 2024 9:25am EDT bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
